Compare The Oncology Institute, Inc. (TOI) vs Tenet Healthcare Corporation (THC) Stock

Tenet Healthcare Corporation (THC) offers the better valuation at 15.8x trailing P/E (14.4x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +355.2%, compared to -72.1% for The Oncology Institute, Inc. (TOI). A $10,000 investment in THC five years ago would be worth approximately $46K today (assuming dividends reinvested). Over 10 years, the gap is even starker: THC returned +815.8% versus TOI's -70.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tenet Healthcare Corporation (THC) is the lower-risk stock at 0.93β versus The Oncology Institute, Inc.'s 1.56β — meaning TOI is approximately 69% more volatile than THC relative to the S&P 500. On balance sheet safety, Tenet Healthcare Corporation (THC) carries a lower debt/equity ratio of 147% versus 34% for The Oncology Institute, Inc. — giving it more financial flexibility in a downturn.

Tenet Healthcare Corporation (THC) is the more profitable company, earning 6.6% net margin versus -16.4% for The Oncology Institute, Inc. — meaning it keeps 6.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16.5% versus -15.3% for TOI. At the gross margin level — before operating expenses — THC leads at 41.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TOI: 75.4% to $5.00.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tenet Healthcare Corporation (THC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93), +815.8% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1.56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (THC: +815.8%, TOI: -70.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: TOI is a small-cap quality compounder stock; THC is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.